HK Stock Market Move | SIPAI HEALTH (00314) surges over 6% after announcing positive earnings, expects a net profit of up to 44 million yuan for the first half of the year; the company's core business shows strong growth.
Sipal Health (00314) shares rose over 6% after the earnings surprise; as of the time of writing, they are up 6.32%, priced at HK$1.43, with a trading volume of HK$906,200.
SIPAI HEALTH (00314) rose over 6% following a positive earnings forecast, reaching a 6.32% increase as of press time, priced at HKD 1.43, with a trading volume of HKD 906,200.
On August 4, SIPAI HEALTH announced its earnings forecast, stating that the group expects to achieve a net profit of HKD 41 million to HKD 44 million in the first half of 2026; normalized net profit is anticipated to be HKD 6 million to HKD 7 million. The announcement indicated that the groups core businesses (specifically enterprise insurance services and physician research assistance) achieved strong growth; at the same time, the proportion of core businesses, which have higher gross profit margins, increased, driving up the groups overall gross profit margin.
Related Articles

CANBRIDGE-B(01228): Richard Arthur Moscicki has been appointed as an independent non-executive director.

US Stock Market Move | Biotech company Attovia Therapeutics (ATTO.US) debuted on NASDAQ, with its share price rising 28.82% on the first day of trading.

LEADS BIOLABS-B(09887): The phase II study of Weixin for the treatment of hepatocellular carcinoma has successfully entered the expansion stage.
CANBRIDGE-B(01228): Richard Arthur Moscicki has been appointed as an independent non-executive director.

US Stock Market Move | Biotech company Attovia Therapeutics (ATTO.US) debuted on NASDAQ, with its share price rising 28.82% on the first day of trading.

LEADS BIOLABS-B(09887): The phase II study of Weixin for the treatment of hepatocellular carcinoma has successfully entered the expansion stage.

RECOMMEND





